New drug approved for those with KRAS G-12C
The FDA based their approval on the results of the clinical trial KRYSTAL-1 which showed that a high percentage of patients receiving Krazati were more likely to respond to treatment and have a longer duration of response.
The FDA based their approval on the results of the clinical trial KRYSTAL-1 which showed that a high percentage of patients receiving Krazati were more likely to respond to treatment and have a longer duration of response.
